Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals (Nasdaq: MIRM) presented late-breaking Phase 2b data at EASL 2026. In PSC, volixibat reduced cholestatic pruritus by 2.72 points (placebo-adjusted -1.64; p<0.0001) with 56% vs 26% achieving ≥2-point itch reduction. In HDV, brelovitug met a Week-24 endpoint in 45%/35% vs 0% (delayed). In PFIC, LIVMARLI improved event-free survival vs NAPPED (HR 0.29).
How this was made
The 30-second read
Why it matters
The key trading hook is regulatory timing for volixibat (pre-NDA meeting in summer 2026; NDA in 2H 2026) plus quantified efficacy/survival improvements for existing and investigational therapies, which can shift probability-weighted valuation and near-term sentiment.
Market read
Material pipeline readouts plus explicit regulatory milestones make this a catalyst-style update rather than a recap.
What to watch
For brelovitug, the article truncates the virologic response details and relies on composite/Week 24 measures; investors may wait for Phase 3 AZURE-1/AZURE-4 toplines in H2 2026 to confirm magnitude and consistency.
Background
Mirum is advancing rare liver disease programs: volixibat for PSC, brelovitug for HDV, and maralixibat (LIVMARLI) for PFIC; new EASL 2026 data are presented as late-breaking updates.
Ticker impact
Mirum presented late-breaking Phase 2b VISTAS (volixibat in PSC), Phase 2b AZURE-1 (brelovitug in HDV), and PFIC LIVMARLI data, supporting planned NDA/BLA timelines.
Near-term: positive bias as traders price higher NDA/BLA odds; medium-term: follow-through depends on FDA feedback at the summer 2026 pre-NDA meeting and upcoming Phase 3 toplines (H2 2026).
The article includes multiple statistically supported efficacy endpoints, explicit regulatory timing (pre-NDA meeting and planned NDA submission), and a quantified survival benefit analysis for LIVMARLI, all directly tied to Mirum’s pipeline.
Market effects
Reinforces investor appetite for rare-disease hepatology IBAT inhibition/HDV antiviral franchises; may lift comps’ sentiment even without new peer-specific catalysts.
Primarily US-listed biotech sentiment; EASL timing can drive Europe/US cross-market attention for hepatology rare disease.
Supports global rare-liver disease treatment narratives and may influence expectations for upcoming international regulatory discussions.
Counterpoint
Congress presentations can overstate durability/clinical relevance versus full regulatory-grade datasets; safety signals (GI events, liver enzyme elevations) could temper enthusiasm.
Key entities
- companyMirum Pharmaceuticals, Inc.
Subject of the article; presented new clinical data and reiterated planned NDA/BLA timelines.
- drugvolixibat
IBAT inhibitor candidate in Phase 2b VISTAS for PSC; presented with statistically significant pruritus and bile acid reductions.
- drugbrelovitug
Candidate in Phase 2b AZURE-1 for chronic HDV; presented with composite endpoint and ALT normalization results at Week 24.
- drugLIVMARLI (maralixibat)
Approved therapy for pediatric cholestatic pruritus/PFIC; presented analysis showing improved event-free survival in PFIC.
- regulatorU.S. FDA
Will host a pre-NDA meeting for volixibat in summer 2026 per the company.
